Cartesian Therapeutics (RNAC) Company Report

Cartesian Therapeutics reported cash resources of approximately $145.1 million as of September 30, 2025, which are expected to fund planned operations into mid-2027.
Enrollment for the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis remains on track, with the company projecting a $1B+ market opportunity in this indication.
The FDA accepted the Investigational New Drug (IND) application for Descartes-08 in myositis, with a Phase 2 seamless adaptive clinical trial expected to commence in 1H 2026, representing a potential multi-billion-dollar market opportunity.
A Phase 1/2 pediatric trial of Descartes-08 for juvenile dermatomyositis was initiated, following the FDA's Rare Pediatric Disease Designation for the treatment.

Jan 9, 2026, 1:06 PM

Cartesian Therapeutics Announces Positive Phase 2 SLE Data for Descartes-08, Prioritizes Myositis Expansion, and Updates Cash Runway

RNAC

New Projects/Investments

Guidance Update

Cartesian Therapeutics reported positive initial data from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus (SLE), observing a 100% LLDAS response rate in three patients at Month 3 follow-up and a favorable safety profile.
The company plans to pause further development of Descartes-08 in SLE and Descartes-15 in multiple myeloma to prioritize Descartes-08 for myasthenia gravis (MG), which is in Phase 3, and for myositis, with a Phase 2 trial planned to commence in the first half of 2026.
Cartesian Therapeutics expects its current cash resources to fund planned operations through mid-2027, covering the completion of the Phase 3 MG trial and initiation of the Phase 2 myositis trial.